Mayo Clinic Proceedings Home
MCP Digital Health Home
Original article| Volume 96, ISSUE 12, P3021-3029, December 2021

Antidiabetic Effects of the Senolytic Agent Dasatinib

Published:November 09, 2021DOI:



      To evaluate the antidiabetic effects of the senolytic agent dasatinib in older patients with type 2 diabetes mellitus.


      This retrospective cohort study included enterprise-wide Mayo Clinic patients using Informatics for Integrating Biology at the Bedside from January 1994 through December 2019. The antidiabetic outcomes (change in hemoglobin A1c value, serum glucose concentration, and diabetic medications) after 1 year of a strongly senolytic tyrosine kinase inhibitor, dasatinib (n=16), was compared with a weakly senolytic tyrosine kinase inhibitor, imatinib (n=32).


      Relative to imatinib, patients treated with dasatinib had a mean reduction of 43.7 mg/dL (P=.005) in serum glucose concentration (to convert glucose values to mmol/L, multiply by 0.0555) and required 28.8 fewer total daily insulin units (P=.08) in the setting of a 4.8-kg relative weight loss (5.3% of total body weight; P=.045). Linear regression analysis suggests that the relative difference in weight accounts for 8.4 mg/dL of the 43.7 mg/dL blood glucose value decrease, or 19.2%. Relative to imatinib, patients treated with dasatinib had a mean 0.80 absolute point (P=.05) reduction in hemoglobin A1c and required 18.2 fewer total daily insulin units (P=.16) in the setting of a 5.9-kg relative weight loss (6.3% of total body weight; P=.06).


      Dasatinib may have antidiabetic effects comparable to contemporary diabetic treatments and may be considered for use as a novel diabetic therapy. Future studies are needed to determine whether these results are translatable to patients with type 2 diabetes mellitus without underlying malignant diseases and to determine whether the antidiabetic effects of dasatinib are due to its senolytic properties.

      Abbreviations and Acronyms:

      T2DM (type 2 diabetes mellitus), TKI (tyrosine kinase inhibitor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. IDF Diabetes Atlas.
        Date accessed: April 1, 2020
        • Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020
        Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, Atlanta, Ga2020
        • Breccia M.
        • Muscaritoli M.
        • Aversa Z.
        • Mandelli F.
        • Alimena G.
        Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
        J Clin Oncol. 2004; 22: 4653-4655
        • Veneri D.
        • Franchini M.
        • Bonora E.
        Imatinib and regression of type 2 diabetes.
        N Engl J Med. 2005; 352: 1049-1050
        • Breccia M.
        • Muscaritoli M.
        • Cannella L.
        • Stefanizzi C.
        • Frustaci A.
        • Alimena G.
        Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
        Leuk Res. 2008; 32: 1626-1628
        • Huda M.S.
        • Amiel S.A.
        • Ross P.
        • Aylwin S.J.
        Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
        Diabetes Care. 2014; 37: e87-e88
        • Brooks M.B.
        Erlotinib appears to produce prolonged remission of insulin requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease.
        Br J Diabetes Vasc Dis. 2012; 12: 87-90
        • Iizuka K.
        • Niwa H.
        • Kato T.
        • Takeda J.
        Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia.
        BMJ Case Rep. 2016; 2016 (bcr2015214284)
        • Agostino N.M.
        • Chinchilli V.M.
        • Lynch C.J.
        • Koszyk-Szewczyk A.
        • Gingrich R.
        • Sivik J.
        • et al.
        Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
        J Oncol Pharm Pract. 2011; 17: 197-202
        • Breccia M.
        • Molica M.
        • Alimena G.
        How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
        Leuk Res. 2014; 38: 1392-1398
        • Dingli D.
        • Wolf R.C.
        • Vella A.
        Imatinib and type 2 diabetes.
        Endocr Pract. 2007; 13: 126-130
        • Mariani S.
        • Tornaghi L.
        • Sassone M.
        • Basciani S.
        • Buzzetti R.
        • Gambacorti-Passerini C.
        • et al.
        Imatinib does not substantially modify the glycemic profiles in patients with chronic myeloid leukaemia.
        Leuk Res. 2010; 34: e5-e7
        • Palmer A.K.
        • Tchkonia T.
        • LeBrasseur N.K.
        • Chini E.N.
        • Xu M.
        • Kirkland J.L.
        Cellular senescence in type 2 diabetes: a therapeutic opportunity.
        Diabetes. 2015; 64: 2289-2298
        • Palmer A.K.
        • Xu M.
        • Zhu Y.
        • Pirtskhalava T.
        • Weivoda M.M.
        • Hachfeld C.M.
        • et al.
        Targeting senescent cells alleviates obesity-induced metabolic dysfunction.
        Aging Cell. 2019; 18: e12950
        • Zhu Y.
        • Tchkonia T.
        • Pirtskhalava T.
        • Gower A.C.
        • Ding H.
        • Giorgadze N.
        • et al.
        The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs.
        Aging Cell. 2015; 14: 644-658
        • Nathan D.M.
        • Buse J.B.
        • Davidson M.B.
        • Ferrannini E.
        • Holman R.R.
        • Sherwin R.
        • et al.
        • American Diabetes Association; European Association for Study of Diabetes
        Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2009; 32: 193-203
        • Shantha G.P.
        • Kumar A.A.
        • Kahan S.
        • Cheskin L.J.
        Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study.
        Diabetes Educ. 2012; 38: 417-426
        • Ono K.
        • Suzushima H.
        • Watanabe Y.
        • Kikukawa Y.
        • Shimomura T.
        • Furukawa N.
        • et al.
        Rapid amelioration of hyperglycemia facilitated by dasatinib in chronic myeloid leukemia patient with type 2 diabetes mellitus.
        Intern Med. 2012; 51: 2763-2766
        • Chodorowski Z.
        • Sein Anand J.
        • Hellmann A.
        • Prejzner W.
        [No influence of imatinib on type 2 diabetes.].
        Przegl Lek. 2007; 64: 370-371
        • Fountas A.
        • Diamantopoulos L.N.
        • Tsatsoulis A.
        Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? [erratum appears in Trends Endocrinol Metab. 2016;27(1):65].
        Trends Endocrinol Metab. 2015; 26: 643-656
        • Minamino T.
        • Orimo M.
        • Shimizu I.
        • Kunieda T.
        • Yokoyama M.
        • Ito T.
        • et al.
        A crucial role for adipose tissue p53 in the regulation of insulin resistance.
        Nat Med. 2009; 15: 1082-1087
        • Kitada K.
        • Nakano D.
        • Ohsaki H.
        • Hitomi H.
        • Minamino T.
        • Yatabe J.
        • et al.
        Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.
        J Diabetes Complications. 2014; 28: 604-611
        • Pignolo R.J.
        • Passos J.F.
        • Khosla S.
        • Tchkonia T.
        • Kirkland J.L.
        Reducing senescent cell burden in aging and disease.
        Trends Mol Med. 2020; 26: 630-638
        • Yousefzadeh M.J.
        • Zhu Y.
        • McGowan S.J.
        • Angelini L.
        • Fuhrmann-Stroissnigg H.
        • Xu M.
        • et al.
        Fisetin is a senotherapeutic that extends health and lifespan.
        EBioMedicine. 2018; 36: 18-28

      Linked Article

      • In the Limelight: December 2021
        Mayo Clinic ProceedingsVol. 96Issue 12
        • Preview
          This month’s feature highlights three articles that appear in the current issue of Mayo Clinic Proceedings. These articles are also featured on the Mayo Clinic Proceedings’ YouTube Channel ( ).
        • Full-Text
        • PDF